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EarAbstract Introduction: Audiovestibular dysfunction has been reported in connective tissue disease
patients. Evaluation of the otolith organ function as a part of the vestibular system of the inner ear
in systemic sclerosis (SSc) patients is still greatly uncovered in the literature.
Aim of work: To assess otolith function in SSc patients and to correlate the ﬁndings with the clin-
ical characteristics and disease severity.
Patients and methods: Thirty SSc patients and 30 matched controls were included in this work.
All patients were subjected to full history taking, clinical examination, assessment disease severity
by modiﬁed Rodnan skin score (mRss), relevant laboratory and radiological tests. All patients had
otolith function assessment using Vestibular Evoked Myogenic Potentials (VEMP) and auditory
assessment done using pure tone audiometry (PTA), speech audiometry and tympanometry.
Results: Auditory assessment revealed bilateral sensorineural hearing loss (SNHL) in 11 (36.6%)
patients an abnormal VEMP response was found in 24 (80%). The mean latencies of P13 and N23
were signiﬁcantly prolonged than in the controls (p< 0.001). Sine scleroderma subtype was
signiﬁcantly more frequent in SSc patients with normal VEMP (p= 0.04). Skin thickening was sig-
niﬁcantly more frequent in those with abnormal VEMP (p= 0.04) and the mRss score was also sig-
niﬁcantly increased (p= 0.007). Those with hearing loss were signiﬁcantly older in age (p= 0.03)
and had a signiﬁcantly longer disease duration (p= 0.01) and had a signiﬁcantly increased frequen-
cy of digital pitting (p= 0.02) and ulcers (p= 0.03) compared to those with normal hearing.
Conclusion: Our results showed an evidence of inner ear involvement in SSc causing
audiovestibular abnormalities.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Rheumatic Diseases.1. Introduction
Systemic sclerosis (SSc) is an autoimmune connective tissue
disease (CTD) described for the ﬁrst time in the middle of
the 19th century [1]. The term systemic sclerosis is used to
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them together, whereas a highly variable clinical course exists
that spans from mild and subtle ﬁndings to aggressive, life-
threatening multisystem disease [2].
Systemic sclerosis (SSc) is characterized by ﬁbrosis; mainly
in the skin; vasculopathy with Raynaud’s phenomenon as an
almost universal symptom as well as the presence of autoanti-
bodies. Vasculopathy is a major factor in the symptoms and
morbidity of SSc, probably occurring as the result of an
autoimmune insult triggered by an as yet unknown factor that
causes inﬂammatory processes and ultimately ﬁbrosis with col-
lagen deposition. The involvement of vessels characterized by
intimal proliferation of the arteries that is ubiquitous in this
disease and this vasculature involvement is fundamental to
organ damage and subsequent malfunction [3]. Insufﬁcient
angiogenesis with tissue ischemia and accumulation of extra-
cellular matrix represent the hallmarks of SSc disease [4].
There is some evidence of hearing loss in other autoimmune
diseases, mainly caused by cochlear – vestibular abnormalities,
and with vasculitis as the most accepted hypothesis [5].
The vestibular system comprises two types of sensory
organs – the semicircular canals and the otolith organs (the
saccule and utricle). The two otolith organs are positioned per-
pendicular to each other and sense linear acceleration, head
tilt, and gravity, with the primary role of providing input to
the vestibulospinal reﬂex for postural stability [6]. The vestibu-
lar sensory epithelium of the otolith organ is located on the
maculae of the saccule and utricle. The sensory cells, hair cells
of the maculae, are embedded in a gelatinous layer and above
this is a ﬁbrous structure, the otolithic membrane, in which are
embedded crystals of calcium carbonate called otoconia [7].
These delicate structures are liable to ﬁbrosis in SSc, which
in turn may lead to otolith dysfunction.
Vestibular Evoked Myogenic Potentials (VEMPs) are short-
latency electromyograms evoked by high-level acoustic stimuli
recorded from surface electrodes over the tonically contracted
sternocleidomastoid (SCM) muscle, as they are used to evalu-
ate otolith function [8]. There are few studies in the literature
regarding hearing disorders [9], and vestibular dysfunction
[10–12] in SSc. However, there is no study that evaluated oto-
lith organ function as a part of vestibular system.
The aim of our work is to evaluate otolith vestibular func-
tion in patients with SSc and to correlate these ﬁndings with
age, disease duration and different clinical parameters among
patients with SSC.2. Patients and methods
The present study included two groups; patient group included
thirty with SSc patients who fulﬁlled the 2013 American Col-
lege of Rheumatology/European League Against Rheumatism
(ACR/EULAR) criteria for the classiﬁcation of SSc [13],
recruited over a period of 1 year from the Rheumatology
and Rehabilitation Outpatient Clinic and/or Department,
Kasr El-Aini Hospital, Cairo University. The Control group
was comprised of thirty age and sex matched healthy adults.
The study was approved by the Institutional Review Board
(IRB), and all cases signed a written informed consent.
The SSc patients were further subgrouped according to the
classiﬁcation system proposed by Le Roy et al. into limited
cutaneous SSc (lSSc) and diffuse cutaneous SSc (dSSc) [14].Scleroderma patients with ear trauma, operations or infec-
tions, or use of ototoxic drugs as salicylates, non-steroidal
anti-inﬂammatory drugs (NSAID), quinine, all were excluded
from our study.
All patients have been subjected to:
I. Comprehensive history taking including personal, pre-
sent, family and past history. Systemic manifestations
and the history of drug intake were also recorded.
II. Thorough clinical examination including cutaneous, gas-
trointestinal, cardiopulmonary, neurological, rheumato-
logical and otological examination (including otoscopic
examination).
Tenderness score was recorded according to Ritchie articu-
lar index [15]. The skin thickness was scored according to the
modiﬁed Rodnan Skin Score (mRss), [16] in which the body
was divided into 17 areas and the degree of thickness is graded
at each site, scoring each area from 0 to 3 where (0) is normal
skin, and (3) is extreme thickening. The sum of the score of all
palpated sites is documented with a maximum possible score
of 51.
III. Investigations:
A- Laboratory investigations included complete blood pic-
ture (CBC), erythrocyte sedimentation rate (ESR), liver
and renal function tests, urine analysis, creatine phos-
phokinase (CPK), rheumatoid factor using the latex
agglutination method, antinuclear antibodies (ANA)
and its pattern.
B- Radiological investigations included plain X-ray chest for
detection of pulmonary inﬁltrates, interstitial lung ﬁbro-
sis and dilated pulmonary artery; high resolution com-
puterized tomography (HRCT) chest for detection and
description of interstitial pulmonary ﬁbrosis; and Dop-
pler echocardiography for cardiac assessment.
C- Auditory investigations: All the following measures were
done by an expert Audiologist:
1- Pure Tone Audiometry (PTA): Air conduction (AC) on
the better ear was started as the patient wears earphones
attached to the audiometer. Pure tones of controlled
intensity were delivered to one ear at a time. The dura-
tion of the test tone is usually kept constant at some
1.5 s: Start at 1000 Hz at 40 dB, down by 10 dB until
no response and then up by 5 dB until there is a
response. After the threshold for the 1 kHz-tone has
been recorded by the audiologist; the entire procedure
is repeated with a 2 kHz tone, and further increasing
the tone’s frequency to 4, 8 and 12 kHz. After the high-
frequency range has been tested, the same procedure is
performed for the lower frequencies, starting again with
a 1 kHz-tone, but decreasing to 0.5, 0.25 kHz.
The same procedure was used for bone conduction with fre-
quencies 0.5–4 kHz. The headband is ﬁtted with small plastic
rectangles that are placed behind the ears so as to channel
the tones through the bones of the skull. The patient feels
the vibrations of the tones as they are transmitted through
the bones to the inner ear. Results were plotted in the audio-
gram showing hearing loss as a function of frequency. Hearing
was scaled according to the average threshold level into nor-
mal hearing (0–25 dB) and hearing loss which could be mild
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70 dB), severe (71–90 dB) and profound (>90 dB) [17].
2- Acoustic Immittance Testing including tympanometry
and acoustic reﬂexes [18] were performed to rule out
middle ear disease (e.g., secretory otitis media), which
is one of the exclusion criteria.
3- Speech audiometry: It is another type of hearing test that
uses a series of simple recorded words spoken at various
volumes directly into earphones worn by the patient.
The speech reception threshold (SRT) is the lowest inten-
sity level at which a patient can correctly repeat 50% of
common bisyllabic words. These results should corre-
spond with pure-tone thresholds. Word recognition test-
ing (formerly referred to as speech discrimination
testing) assesses a patient’s ability to identify monosyl-
labic words and the percentage that the subject can
repeat correctly. It is done by presenting a list of words
to the patient at a suprathreshold level at approximately
40 dB above the SRT [19].
4- Vestibular Evoked Myogenic Potentials (VEMP): The
VEMP is a simple non invasive test, with about 15 min
duration. First the skin is cleansed before application
of the electrodes to ensure that the impedance is less
than 5 K X. The active (positive) electrode (right then
left) is placed on the middle of the sterno-cleido-mastoid
muscle; the inverting (negative) electrode is placed on
the upper sternum (suprasternal notch); and the ground
electrode on the other side.
Recording technique: Two repeatable recordings are
obtained. Patients are given 30–60 s to relax between each
recording to avoid fatigue. They were asked to ﬂex the neck
against resistance.
Stimulus parameters: The stimulus type used was tone
burst, of a rarefaction polarity; 1 ms rise/fall time and 2 ms
plateau, Blackman ramp; and intensity was presented through
the TDH39 headphones. Stimulus rate was 5/s. At least 100
sweeps were averaged. The stimulus intensity level of
95 dBnHL was used as a default starting intensity; two trials
were obtained at each intensity to ensure the reproducibility.
The stimulus intensity was decreased in 10 dB steps or
increased in 5 dB steps depending upon the presence or
absence of VEMP response. The lowest intensity at which a
clear and repeatable biphasic wave observed was considered
the VEMP threshold. VEMP amplitude, P13 and N23 latencies
were measured at a stimulus level of 95 dBnHL.
VEMP responses were judged as either present or absent
according to the presence or absence of P13–N23 biphasic
response. Parameters analyzed in the preserved VEMP
responses were wave latencies and amplitudes. P13 and N23
latencies (ms) are the time from the onset of the stimulus to
the peak. The peak-to-peak amplitude (lV) is considered at
the ﬁrst positive–negative peak (P13–N23) [20].
Statistical methods: Data were coded and entered using the
statistical package SPSS version 21. Data were summarized
using mean and standard deviation for quantitative variables
and frequencies (number of cases) and relative frequencies
(percentages) for categorical variables. Comparisons between
quantitative variables in cases and control were done using
unpaired T test, while comparisons between quantitative vari-
ables in scleroderma cases were done using the non-parametri-cal Mann–Whitney test. For comparing categorical data, Chi
square (v2) test was performed. Exact test was used instead
when the expected frequency is less than 5. Correlations were
done between quantitative variables using Spearman correla-
tion coefﬁcient. P-values less than 0.05 were considered as sta-
tistically signiﬁcant.3. Results
The present study included 30 SSc patients, 26 of them were
females (86.7%) and 4 males (13.3%), and their age ranged
from 21 to 60 years, with a mean of 40.1 ± 11.9 years. Thirty
otologically healthy controls, whom were age and sex matched,
were also included in this study, with a mean age of
45.2 ± 11.6 years. The age of onset of SSc ranged from 15
to 58 years with a mean of 35.30 ± 12.07 years, while the dis-
ease duration ranged from 0.5 to 20 years with a mean of
5.98 ± 5.4 years. Among SSc patients, 21 (70%) had limited
SSc, 4 (13.3%) had diffuse SSc, and 5 (16.7%) patients had
sine scleroderma SSc.
The demographic and clinical characteristics of SSc patients
are shown in Table 1. The modiﬁed Rodnan Skin Score (mRss)
ranged from 0 to 45, with a mean of 14.2 ± 11.3. The Tender
Joint Count (TJC) of SSc patients ranged from 0 to 28 with a
mean of 3.4 ± 6.2 joints.
Table 2 shows the laboratory and immunological proﬁle,
radiological ﬁndings and immunosuppressive drug intake of
the SSc patients. Elevated ESR was shown in 19/30 patients,
anemia in 10/30, leukocytosis in 5/30, leuckpenia in 2/30,
thrombocytopenia in 2/30, and thrombocytosis in 2/30
patients. Among our patients, only 2 had microalbuminuria.
Among our SSc patients, audiovestibular symptoms includ-
ed hearing loss in 13 (43%) patients, vertigo in 18 (60%), tin-
nitus in 6 (20%) and no one gave a history of earache. Five
patients (16.6%) had subjective hearing loss, while 3 (10%)
had asymptomatic hearing loss. Otoscopic examination was
normal for all patients. Pure tone audiometry (PTA) showed
11 (36.6%) patients with hearing loss while the control group
was within normal. All patients had speech audiometry thresh-
olds matched with PTA and the Word recognition testing
scores ranging from 96% to 100%. All patients had normal
type (A) tympanogram and normal acoustic reﬂex threshold
indicating normal middle ear and tympanic membrane.
Among SSc patients, 11 (36.6%) have bilateral sensorineu-
ral hearing loss (SNHL), which was mild in 4 patients, moder-
ate in 6, and moderate to severe in one patient. Seven patients
had SNHL at high frequencies. Fig. 1 shows the average
audiogram in SSc patients with SNHL compared to the con-
trol. The mean values of the air-conduction hearing thresholds
in SSc patients with hearing loss were poorer than those in the
control group for frequencies 250, 500, 1000, 2000, 4000 and
8000 Hz Table 3 shows the PTA thresholds of the SSc patients
and controls.
On comparing the clinical and investigational characteris-
tics between SSc patients with hearing loss (n= 11) and those
with normal hearing (n= 19) those with hearing loss were sig-
niﬁcantly older in age (46.5 ± 11.8 years) (p= 0.03) and had a
signiﬁcantly longer disease duration (9 ± 6.1 years) (p= 0.01)
compared to those with normal hearing (36.5 ± 10.6 years and
4.2 ± 4.1 years, respectively). Patients with hearing loss had
signiﬁcantly increased frequency of digital pitting and ulcers
Table 1 Demographic and clinical characteristics of systemic
sclerosis (SSc) patients.
Characteristic SSc patients (N= 30)
Demographic Mean ± SD
Age (years) 40.1 ± 11.9
Age of onset (years) 35.3 ± 12.1
SSc duration (years) 5.98 ± 5.4
SSc subtypes n (%)
Limited 21 (70)
Diﬀuse 4 (13.3)
SSc sine scleroderma 5 (16.7)
Clinical n (%)
Constitutional
Fever 1 (3.3)
Weight loss 23 (76.7)
Fatigue 11 (36.7)
Vascular
Raynaud’s phenomenon 30 (100)
Digital pitting 19 (63.3)
Digital ulcers 14 (46.7)
Digital gangrene 8 (26.7)
Telangiectasia 15 (50)
Cutaneous
Skin thickening 25 (83.3)
Hypopigmentation 17 (56.7)
Hyperpigmentation 22 (73.3)
Calcinosis 8 (26.7)
Finger puﬃness 14 (46.7)
Sclerodactyly 25 (83.3)
Gastrointestinal
Esophageal dysmotility 18 (60)
Constipation 9 (30)
Cardiopulmonary
Dyspnea 26 (86.7)
Cough 9 (30)
Elevated S2 8 (26.7)
Crepitations 12 (40)
Musculoskeletal
Arthralgia 9 (30)
Arthritis 7 (23.3)
Peripheral neuritis 10 (33.3)
Sicca symptoms 4 (13.3)
mean ± SD
Skin severity (mRss) 14.7 ± 11.3
Tender Joint Count 3.4 ± 6.2
SSc, systemic sclerosis; mRss, Modiﬁed Rodnan Skin Severity;
TJC, Tender Joint Count.
Table 2 Laboratory and radiological ﬁndings and immuno-
suppressive drugs used by the systemic sclerosis (SSc) patients.
Variable SSc patients (N= 30)
Immunological n (%)
Antinuclear antibody (ANA) +ve 23 (76.7)
Pattern
Speckled 18 (60)
Homogenous 3 (10)
Nucleolar 8 (26.7)
Centromere 2 (6.7)
Laboratory mean ± SD
Erythrocyte sedimentation rate (mm/1st h) 38.2 ± 20.3
Hemoglobin content (g/dl) 11.97 ± 4.6
Total leukocytic count (·103/mm3) 8.1 ± 3.2
Platelet count (·103/mm3) 270.6 ± 72.9
Urinary proteins (gm/24 h) 0.04 ± 0.1
Aspartate transaminase (U/L) 24.2 ± 11.9
Alanine transaminase (U/L) 25.2 ± 14.5
Creatinine phosphokinase (IU/L) 93.9 ± 60.3
Creatinine (mg/dl) 0.68 ± 0.18
Radiological n (%)
Pulmonary artery hypertension 10 (33)
Interstitial pulmonary ﬁbrosis (IPF) 19 (65.5)
IPF (Ground glass) 17 (56.7)
IPF (honey combing) 6 (20)
Immunosuppressives n (%)
Corticosteroids 13 (43.3)
Methotrexate 7 (23.3)
Cyclophosphamide 12 (40)
Azathioprine 4 (13.3)
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and 32%) (p= 0.02 and p= 0.03, respectively). All other clin-
ical, laboratory, radiological characteristics as well as the fre-
quency of drug intake were comparable between those with
and without hearing loss.
Assessment of otolith function for 60 ears of the SSc
patients and the controls was done using Vestibular Evoked
Myogenic Potentials (VEMP) where the latencies at P13
and N23 in the patients were signiﬁcantly prolonged
(18.5 ± 3.4 ms and 27.7 ± 3.4 ms, respectively) compared to
the control (12.84 ± 0.8 ms and 19.9 ± 2.5 ms, respectively)
(p< 0.001). The mean amplitude was signiﬁcantly higher
(68.8 ± 50.7 mv) in patients compared to control
(30.89 ± 4.35 mv) (p< 0.001).Regarding the VEMP abnormalities observed in SSc
patients, 14 (58.3%) patients showed delayed P13 and N23
latencies in both ears, 6 (25%) patients showed absent VEMP
response in both ears, 4 patients showed absent VEMP respon-
se in the left ear and was delayed on the right side. According-
ly, VEMP abnormalities were found in 24 (80%) of the SSc
patients (Fig. 2).
On comparing between SSc patients with normal and
abnormal VEMP regarding vertigo, those with abnormal
VEMP had vertigo in 16/24 (66.7%) while those with normal
VEMP showed vertigo in 2/6 (33.3%) of the patients. No sig-
niﬁcant difference was elicited in VEMP state between SSc
patients with and without vertigo (p= 0.18). Regarding the
hearing loss, as assessed by the PTA, it was evidenced in 1/6
(16.7%) of patients with normal VEMP compared to 10/24
(41.7%) of those with abnormal VEMP (p= 0.37).
Sine scleroderma subtype was signiﬁcantly more frequent in
SSc patients with normal VEMP (3/6) compared to those with
abnormal VEMP (2/24) (p= 0.04). Skin thickening was
signiﬁcantly more frequent in those with abnormal VEMP
(22/24) compared to those with normal VEMP (3/6)
(p= 0.04) and even a signiﬁcantly higher degree of thickening
as assessed by mRss (16.8 ± 10.9) in those with abnormal
VEMP compared to those with normal VEMP (3.7 ± 5.4,
p= 0.007). No statistically signiﬁcant difference was detected
between SSc patients with normal and abnormal VEMP
regarding the other clinical characteristics, laboratory ﬁndings,
radiological workup, or according to the immunosuppressive
drugs used by these patients.
Figure 1 Mean values of PTA thresholds of all SSc patients (60 ears) as compared to the control group (60 ears) and SSc patients with
hearing loss (22 ears).
Table 3 Comparison between pure tone audiometry (PTA)
results of systemic sclerosis (SSc) patients and control.
Frequency (Hz) PTA Thresholds p value
Patients (60 ears) Controls (60 ears)
250 19.2 ± 8.2 17.0 ± 3.8 0.067
500 20.0 ± 8.8 16.0 ± 4.9 0.003*
1000 20.8 ± 8.9 15.3 ± 4.3 <0.001**
2000 19.8 ± 8.9 14.7 ± 5.2 <0.001**
4000 24.6 ± 11.3 16.8 ± 3.4 <0.001**
8000 32.2 ± 17.6 18.0 ± 2.2 <0.001**
* Signiﬁcant (p< 0.05).
** Highly signiﬁcant (p< 0.001).
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according to the presence or absence of the clinical, laboratory
or radiological features, no signiﬁcant difference was found
except for a signiﬁcantly shorter latency (22.6 ± 1.99 ms) in
those with a homogenous ANA pattern compared to those
without (27.9 ± 3.3 ms) (p= 0.03).
Correlation was signiﬁcant between the N23 latency (ms)
and degree of skin thickening as assessed by mRss (p= 0.02)
and negatively signiﬁcant with the total leukocytic count
(p= 0.02). No signiﬁcant correlation could be found with
any of the other characteristics.
4. Discussion
Systemic sclerosis (SSc) is a multisystem connective tissue dis-
ease affecting the skin and internal organs. The hallmarks of
SSc are autoimmunity, inﬂammation, functional and struc-
tural abnormalities in small blood vessels in multiple vascular
beds, and progressive ﬁbrosis of the skin and internal organs
[21]. In primary and secondary autoimmune inner ear disease
(AIED), immune reactions and subsequent damages occur
[22]. Inner ear involvement in systemic autoimmune diseases
can be either due to direct autoimmune reactions or due to vas-
culopathy or vasculitis [23]. Few researches showed inner ear
involvement in SSc addressing audiovestibular affection as a
manifestation [9–12], however, to our knowledge; the affection
of otolith organs in SSc patients was not as such studied. Theaim of the present study was to assess otolith function in SSc
patients by VEMP, where an abnormal response indicates an
abnormal vestibulospinal reﬂex and to study the relation of
our ﬁndings with different disease characteristics.
The SSc patients’ age ranged from 21 to 60 years with a
mean of 40.1 ± 11.9 years. The age at disease onset ranged
from 15 to 58 years with a mean of 35.30 ± 12.07 years. The
disease duration ranged from 0.5 to 20 years with a mean of
5.98 ± 5.36 years. Regarding SSc disease subtype, 21 patients
(70%) had limited SSc, 4 (13.3%) had diffuse SSc and 5
(16.7%) patients had sine scleroderma (ssSSc). There were 26
females and 4 males with a F:M ratio 6.5:1. This is in agree-
ment with another study on Egyptian SSc patients with a
F:M ratio of 7:1 [24].
Auditory assessment revealed that 11/30 (36.6%) of SSc
patients have abnormally decreased hearing threshold and
bilateral sensorineural hearing loss (SNHL). Signiﬁcantly
poorer hearing threshold was found in patients compared to
the control at frequencies 500, 1000, 2000, 4000 and
8000 Hz. Seven patients had SNHL at high frequencies only.
Hearing loss was mild in 4 patients, moderate in 6, and mod-
erate to severe in one patient.
This is in agreement with the results of other studies on SSc
patients as Maciaszczyk et al. who found SNHL in 8/20 (40%),
mostly bilateral. They reported a signiﬁcantly poorer hearing
threshold in SSc patients compared to the controls at frequen-
cies 500, 1000, 6000 and 8000 Hz. Hearing loss was mild for 3
patients and moderate for the remaining ﬁve [12]. Monteiro
and his study group found SNHL in 46% of the dcSSc patients
compared to only 19% of the control (p= 0.01) [25]. In anoth-
er study by Amor-Dorado et al., 27/35 (77%) of the lSSc
patients showed abnormal hearing loss in the audiogram com-
pared to only 15/59 (26%) of the controls. Sensorineural hear-
ing loss (SNHL), mostly bilateral, was registered in 24/27 and
3 patients were found to have mixed type due to associated
myringosclerosis evidenced by otoscopic examination [10].
The higher percentage of their results may be attributed to old-
er mean age and the limited SSc subtype of all patients. In
accordance with our ﬁndings, Kastanioudakis et al. revealed
SNHL in 6/30 (20%) patients with a poorer hearing threshold
at mid and high frequencies [26]. In an older study [27] hearing
loss was detected in 14/31 (45%) patients most of them with
SNHL. In a study on 27 Egyptian patients with SSc, SNHL
Figure 2 Vestibular Evoked Myogenic Potentials showing (A)
normal response, (B) delayed response and (C) an absent
responses obtained from SSc patients in the current study.
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90% of these patients and hearing loss was signiﬁcant at all
frequencies [28]. Their cases were different from the patients
included in this study as all were females, of older age, longer
disease duration and had more severe skin thickness as pre-
sented by the higher mRss.
In the present study, we found that 80% of our patients had
abnormal VEMP response. Bilateral delayed P13 and N23
latencies were found in 58.3% of cases, bilateral absent VEMP
response in 25% and unilaterally absent in 16.7% of cases. The
P13 and N23 latencies were signiﬁcantly prolonged than in
controls (p< 0.001). Delayed VEMP indicates that the lesion
is retrolabyrinthine especially in the vestibulospinal tract [29].
In their study, Ribeiro and his colleagues suggested thatperipheral vestibular lesions including lesions in the otolith
organs or vestibular nerve as in Me´nie`re’s disease or vestibular
neuritis are mostly associated with an absent VEMP response
[30]. Furthermore, Akkuzu et al. showed that patients with
peripheral vestibular disorders had prolonged and absent
VEMP responses [31]. In a recent study on systemic lupus ery-
thematosus (SLE) patients, prolonged P13 and N23 latencies
of VEMP were found suggesting a retrolabyrinthine lesion
especially in the vestibulospinal tract [32]. Furthermore, Erbek
and coworkers found that mean P13 and N23 latencies were
prolonged in Behc¸et patients [33]. Vestibular dysfunction was
found in 33% of SSc patients using computerized dynamic
platform posturography which tests the vestibulospinal tract
[11]. In another study, 17% of the SSc patients had vertigo
related to the involvement of the semicircular canals and
41% showed signiﬁcantly increased frequency of abnormal
sensory interaction and balance of vestibular origin [34]. In
another study on Egyptian SSc patients, 70% had an abnor-
mal Transient Evoked OtoAcoustic Emissions (TEOAEs) sug-
gested cochlear hearing loss. In those with normal hearing,
43% showed abnormal TEOAE results suggesting sub-clinical
cochlear outer hair cell affection [28].
Audiovestibular symptoms of our patients included hearing
loss in 13 (43.3%), vertigo in 18 (60%), tinnitus in 6 (20%),
and no one gave a history of earache. Five patients (16.6%)
had subjective hearing loss, while 3 (10%) had asymptomatic
hearing loss.
Vertiginous complaint was found in 16/24 patients with
abnormal VEMP and no remarkable association was found.
These ﬁndings coincide with those of Maciaszczyk et al.,
who detected vertigo in 60% of patients, and hearing loss in
40% as the SNHL was asymptomatic in 37.5% [12]. In anoth-
er study, hearing loss was found in 54%, vertigo in 31%, tin-
nitus in 37% and 20% had subjective hearing loss [10]. Erbek
et al. found no relation between P13 latencies and vertiginous
complaints which may be explained by the partial involvement
of vestibular neurons that is compensated by the central ner-
vous system in some patients [33].
In the present study, hearing loss was signiﬁcantly associat-
ed with older SSc patients (p= 0.03). These ﬁndings are in
agreement with the results of others [10,12] and were in dis-
agreement with the results of another study [26]. Hearing loss
was signiﬁcantly associated with a longer disease duration in
our SSc patients (p= 0.013). In contrast to our ﬁndings other
studies failed to elicit any correlation [10,12,26]. This could be
explained by different samples’ collection. Abnormal vestibu-
lar ﬁndings by VEMP were not associated with age or disease
duration of SSc patients in the present study. This is in agree-
ment with the ﬁndings in other studies [11,28,34].
No relation was found between hearing loss and the disease
subtypes. This was in accordance with the results of Maci-
aszczyk et al. [12] and Kastanioudakis et al. [26]. In the present
work, there was no statistically signiﬁcant difference between
SSc patients with normal and abnormal VEMP regarding dis-
ease subtype except sine scleroderma subtype that was sig-
niﬁcantly associated with normal VEMP (p= 0.04), a
ﬁnding which was not concluded in previous studies in the
literature.
Hearing loss was signiﬁcantly associated with increased fre-
quency of digital pitting (p= 0.02) and ulcers (p= 0.03) and
no signiﬁcant association was found with other clinical and
laboratory parameters. These ﬁndings go in agreement with
Otolith function assessment 111those of the study of Amor-Dorado et al. who concluded that
apart from digital ulcers, no association was found between
other clinical features of lSSc and the presence of abnormal
audiometric tests [10] and with the study of Kastanioudakis
et al. [26].
In our study, we found no statistical signiﬁcant association
between disease severity as measured by modiﬁed Rodnan skin
sore and hearing loss. This is in agreement with the ﬁndings of
others [12]. The present study showed a statistically signiﬁcant
association between abnormal VEMP and a higher mRss in
SSc patients (p= 0.007). Furthermore, a signiﬁcant correlation
was elicited betweenN23 latency andmRss (p= 0.02). In agree-
ment with our result was the study conducted byBassyouni et al.
who found a signiﬁcant difference on comparing the mRss in
SSc patients with vestibular dysfunction to those without
(p= 0.004) [11]. Furthermore, an abnormal TEOAE was sig-
niﬁcantly associated with a higher mRss (p= 0.049) denoting
more outer-hair cell damage with increased disease pathology
[28]. Histologic ﬁndings of a case of SSc are characterized by
enlarged and thickened blood vessels, perivascular ﬁbrosis and
reduced numbers of outer hair cells [35].
Hearing loss did not show any signiﬁcant association with
any other clinical and laboratory parameters. In harmony with
our ﬁndings were the results of another study on Egyptian SSc
patients that reported that the clinical and laboratory ﬁndings
of the disease did not correlate with the studied audiometric
parameters and thus did not seem to affect the degree of hear-
ing loss [28]. Furthermore, in agreement with these ﬁndings,
other studies found no signiﬁcant association [10,12,26].
On investigating the role of drug intake in hearing loss and
abnormal VEMP, no association could be elicited between
them. These ﬁndings agree with those of Maciaszczyk et al.
who found no notable role for immunosuppressive drugs in
hearing loss [12].
As an overall explanation for the ﬁndings in this study, it is
suggested that the autoimmune nature of the disease which
leads to internal vasculopathy and ﬁbrosis is considered a
key-player in the presenting features of the SSc patients.
To conclude, audiovestibular dysfunction in SSc patients is
overlooked although being frequent, yet mostly asymptomatic.
Accordingly, regular audiovestibular assessment using pure
tone audiometry (PTA) and Vestibular Evoked Myogenic
Potentials (VEMP) is highly recommended in SSc patients, in
addition to other vestibular tests that help detect abnormalities
in the semicircular canals of the vestibular apparatus. Further
research on a larger number of SSc patients is recommended to
conﬁrm our results.
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